[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uveitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uveitis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,42,69,92,117,134,177,202,228,260,288,316,342,368,389,411,434],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100632780","a-study-of-uveitis-in-children-18-years-of-age-100632780",false,"NCT07518134","A Study of Uveitis in Children \u003C18 Years of Age","UV1","Inclusion Criteria:\n\n* Age:\n\n  * Incident cases (onset ≤ 6 months) \\\u003C17 years\n  * Established cases (onset \\> 6 months) \\\u003C18 years\n* Diagnosis of any type of uveitis (infectious or noninfectious) in any location except traumatic and post-operative uveitis.\n* Active or inactive uveitis with any treatment status (current \u002F prior \u002F none \\[but under surveillance\\]).\n\nExclusion Criteria:\n\n* Bilateral uveitis with differing etiologies\n* Traumatic uveitis\n* Post-operative uveitis\n* Immediate family member (spouse, biological or legal guardian, child, sibling, parent) who is an investigative site personnel directly affiliated with this study or who is an employee of JAEB Center for Health Research.\n* Ocular disease related to Retinoblastoma, Coat's disease, retinitis pigmentosa, inherited retinal degeneration, Juvenile xanthogranuloma (JXG), or leukemia\u002Fmalignancy within the eye.","ALL","17 Years",{"count":19,"type":20},300,"ESTIMATED","12 Months","OBSERVATIONAL","The goal of this observational study is to collect data regarding clinical features and current\u002Fpast treatments in children under 18 with uveitis. The main questions it aims to answer are:\n\n* What are the frequency of uveitis subtypes in children?\n* What are clinical and demographic characteristics overall and within each type of uveitis?\n\nParticipants will complete one enrollment visit with their doctor. Participants with uveitis onset \\\u003C6 months from enrollment date will also partake in a 12 month chart review.",[25],"Uveitis",[27,28],"pediatric","uveitis","RECRUITING","2026-05-07",{"date":32,"type":33},"2026-05-08","ACTUAL",{"date":35,"type":33},"2026-04-14",{"date":37,"type":20},"2028-04",{"name":39,"class":40},"Jaeb Center for Health Research","OTHER",4,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100635077","phase-2-a-study-of-efficacy-and-safety-of-gensci048-in-subjects-with-active-uveitis-100635077","NCT07547995","A Study of Efficacy and Safety of GenSci048 in Subjects With Active Uveitis.","A Phase II Clinical Study to Assess the Efficacy and Safety of GenSci048 in Subjects With Active Non-infectious Uveitis.","Inclusion Criteria:\n\n1. Age ≥18 years, regardless of gender;\n2. Diagnosed with non-infectious intermediate-, posterior-, or pan-uveitis, and had a medical history of more than 1 yearsince the initial diagnosis;\n3. Must have active disease at the baseline visit;\n4. Must have demonstrated a prior adequate response to oral corticosteroid therapy (equivalent of oral prednisone up to 1 mg\u002Fkg\u002Fday), as judged by the investigator;\n5. No intention to become pregnant and willingness to use highly effective contraception during the study and for 24 weeks after the last dose of study drug;\n6. Able to understand the study procedures, voluntarily agree to participate, provide written informed consent (ICF), and comply with study requirements and complete the study.\n\nExclusion Criteria:\n\n1. Subjects with isolated anterior uveitis;\n2. Subjects with neovascular\u002Fwet age-related macular degeneration, proliferative or severe non-proliferative diabetic retinopathy, or clinically significant macular edema due to diabetic retinopathy;\n3. Subjects with systemic inflammatory diseases requiring continued treatment with oral corticosteroids or prohibited immunosuppressive agents at screening or baselinevisits;\n4. Any of the following:\n\n   Confirmed active tuberculosis (TB) infection, including but not limited to radiologically confirmed active TB; Subjects with latent TB infection or at high risk for TB may be enrolled, provided they are not considered unsuitable by the investigator (e.g., unwillingness to continue anti-TB treatment per local guidelines after entering the study);\n5. Presence of significant comorbidities, including but not limited to: uncontrolled hypertension (≥200\u002F105 mmHg), congestive heart failure (Stage D), or uncontrolled type 1 or type 2 diabetes (fasting blood glucose \\>7.0 mmol\u002FL or random blood glucose \\>11.1 mmol\u002FL); eligibility will be determined at the discretion of the investigator;\n6. Subject has previous exposure toanti-tumor necrosis factor (TNF) therapy or any other biologic therapy with a potential therapeutic impact on non-infectious uveitis (intravitreal anti-VEGF therapy excluded);","18 Years",{"count":51,"type":20},111,"INTERVENTIONAL",[54],"PHASE2","This study is designed to evaluate the efficacy and safety of GenSci048 compared with placebo in subjects with active non-infectious uveitis.",[25],"NOT_YET_RECRUITING","2026-04-21",{"date":60,"type":33},"2026-04-23",{"date":62,"type":20},"2026-06-18",{"date":64,"type":20},"2028-01-13",{"name":66,"class":67},"Changchun GeneScience Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100537124","rchilduvstudy-on-non-infectious-chronic-uveitis-in-pediatric-age-100537124","NCT06273748","RChildUV:Study on Non-infectious Chronic Uveitis in Pediatric Age","Retrospective and Prospective Observational Study on Non-infectious Chronic Uveitis in Pediatric Age","Inclusion Criteria:\n\n* diagnosis of non-infectious chronic uveitis before the age of 16;\n* signed informed consent form.\n\nExclusion Criteria:\n\n* Patients with a diagnosis of infectious uveitis\n* history of malignant pathology,\n* history of demyelinating pathology,\n* history of cerebral vasculitis","1 Year","16 Years",{"count":79,"type":20},290,"Uveitis is an inflammatory disease of the uvea, one of the highly vascularized fundamental structures of the eye. It is a rare condition in children, with an incidence in the pediatric population ranging from 2% to 14% of all uveitis cases. The diagnosis and management of patients with uveitis rely on a multidisciplinary approach involving an ophthalmologist, a rheumatologist, and an infectious disease specialist to establish the correct diagnosis and assess the involvement of other organs. In Italy, there is no national or regional registry for non-infectious chronic uveitis as per the Prime Ministerial Decree (DPCM) of March 3, 2017 (Identification of surveillance systems and registries for mortality, tumors, and other diseases). However, many clinical centers adopt data recording systems to evaluate the quality of care and to study diseases and outcomes. The Universitary Hospital Meyer Institute Research Hospital (IRCCS) is a national referral center for managing these pediatric cases of non-infectious chronic uveitis, estimated to constitute 95% of all pediatric uveitis cases",[25],"2026-03-23",{"date":84,"type":33},"2026-03-27",{"date":86,"type":33},"2022-02-10",{"date":88,"type":20},"2032-05-02",{"name":90,"class":40},"Meyer Children's Hospital IRCCS",19,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":98,"sex":16,"minAge":99,"maxAge":4,"enrollmentInfo":100,"targetDuration":102,"studyType":22,"phases":4,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":68},"100236538","genetics-of-uveitis-100236538","NCT02357238","Genetics of Uveitis","Inclusion Criteria:\n\n* Any patient above with the diagnosis of uveitis.\n* Any patient with a diagnosis of infectious uveitis such as toxoplasmosis retinochoroiditis, herpes associated retinitis.\n\nExclusion Criteria:\n\n* Patients who are unable to give consent\n* Patients in whom an adequated blood sample can not be obtained.",true,"6 Years",{"count":101,"type":20},1500,"10 Years","In order to improve the investigators knowledge about uveitis and the underlying mechanism of disease, the investigators propose collecting blood from patients with uveitis, isolating DNA and sequencing the DNA to identify genetic mutations or associations in these patients.",[25,105],"Infectious Uveitis",[25,107],"Infectious","2026-03-02",{"date":110,"type":33},"2026-03-04",{"date":112,"type":33},"2011-01",{"date":114,"type":20},"2030-01",{"name":116,"class":40},"The Cleveland Clinic",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":98,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":68},"100189809","analysis-of-anterior-chamber-inflammation-by-optical-coherence-tomography-100189809","NCT01746537","Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography","Automated Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography","ATAC","Inclusion Criteria:\n\n* All patients presenting to Cole Eye Institute with uveitis.\n\nExclusion Criteria:\n\n* Inability to provide informed consent, including non-English speaking and cognitively\u002Fmentally impaired.\n* Severe corneal opacities preventing imaging of anterior chamber",{"count":101,"type":20},"A prospective, observational, case series investigating the feasibility of utilizing OCT scans of the anterior chamber of eyes with uveitis.",[25],{"date":110,"type":33},{"date":130,"type":4},"2012-06",{"date":132,"type":20},"2029-06",{"name":116,"class":40},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":98,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":144,"conditions":145,"keywords":161,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":4},"100615866","wide-field-octa-in-ocular-diseases-100615866","NCT07298174","Wide Field OCTA in Ocular Diseases","Wide Field OCTA in Ocular Diseases: a Prospective Observational Study of the Clinical Impact of Wide Field OCTA in Ocular Disease.","WOOD-2025","Inclusion Criteria:\n\n* Age \\> 18 years\n* Both genders\n* Confirmed diagnosis of one of the above diseases\n* Age-related macular degeneration\n* Diabetic retinopathy\n* Myopia\n* Pachychoroid spectrum disease\n* Inherited retinal dystrophy\n* Uveitis\n* Dry eye\n* Visual acuity of at least 1\u002F20\n* Signed informed consent for the participation to the trial.\n\nExclusion Criteria:\n\n* Media opacities\n* Any other eye or systemic condition that may irreversibly impair the results of the study\n* Surgery in the eye in the study, including cataract extraction, in the three months prior to recruitment",{"count":143,"type":20},200,"The main retinal diseases, whether or not associated with specific mutations genetic, cause progressive degeneration of vascular retinal structures and not vascular, resulting in decreased visual function. Often, such diseases affect the noblest part of the retina, called macula. Many retinal diseases can be complicated by choroidal neovascularization which causes frequent bleeding and fluid leakage that accumulates in the subretinal and intraretinal spaces. Although the investigators know many details of each disease affecting the retina, very often the correct diagnostic framework can be complicated, given the presence of morphological elements common to the different pathologies. Similarly, predicting the effect of treatment and the patient's outcome is a constant challenge for the ophthalmologists. Most of the current research has been focused on the assessment of vascular alterations localized in the macula. However, growing evidence highlight the importance of peripheral vascular changes on the outcome of retinal diseases. These changes can be detected only be wide field OCT devices.\n\nOn the other hand, ocular inflammation and hyperemia represent major assessments in anterior segment disorders, such as dry eye disease. The current grading systems of ocular inflammation, redness and hyperemia are characterized by several limitations, thus making these evaluations still mainly confined to the subjective assessment performed by the ophthalmologist. However, the new generation OCT devices may include also an anterior segment module which can reconstruct anterior segment vessels, non-invasively, using the same technology described for retinal diseases.\n\nThe main goal of the study is to evaluate the diagnostic contribution of a new generation wide field OCTA device in ocular diseases, which has recently received CE marking. In particular, the investigators will evaluate this new generation device both in retinal and anterior segments diseases, testing for common points and differences with the standard of care non-invasive diagnostic devices. Secondary outcomes include the assessment of the correlation between the patient's visual function (visual acuity) and morphological changes (standard of care imaging assessment) highlighted by the wide field OCT device, with particular attention to microstructural differences between major ocular diseases and the possible development of non-invasive biomarkers, useful for the diagnosis and follow-up of such pathologies.",[146,147,148,149,150,151,152,153,154,155,156,157,158,25,159,160],"Age - Related Macular Degeneration (AMD)","Diabetic Macular Edema","Diabetic Retinopathy","Myopia","Inherited Retinal Disease","Stargardt Disease","Retinitis Pigmentosa (RP)","Best Disease","Geographic Atrophy","Macular Neovascularisation","Ocular Surface Disease","Central Serous Choroidopathy","Pachychoroid Disease","Vitreoretinal Disease","Retinal Vein Occlusion",[162,163,164,165,166,167],"wide-field octa","multimodal retinal imaging","quantitative imaging","retinal disease","macular disease","ocular surface disease","2025-12-22",{"date":170,"type":33},"2025-12-30",{"date":172,"type":20},"2026-01",{"date":174,"type":20},"2028-05",{"name":176,"class":40},"IRCCS San Raffaele",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":186,"conditions":187,"keywords":190,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":68},"100590956","metagenomics-for-ocular-inflammation-100590956","NCT06974162","Metagenomics for Ocular Inflammation","Metagenomic Sequencing of Ocular Fluids in Patients With Ocular Inflammation","Inclusion Criteria:\n\n1. 18 years of age or older with the capacity to consent\n2. Standard of care has not determined a clinical diagnosis\n3. Active ocular inflammation with risk of visual loss\n4. Clinically suspected infectious or para-infectious cause of ocular inflammation\n\nExclusion Criteria:\n\n1. Contraindication to ocular fluid sampling\n2. Where an urgent result within 5 days is clinically required",{"count":185,"type":20},36,"The aim of this study is to apply a diagnostic test called 'metagenomic sequencing' to identify the involvement of potential infections in patients with ocular inflammation, where this hasn't been detected by currently available standard testing. For many people with ocular inflammation, no cause is ever found for their disease. In some cases, an infection or infectious trigger is suspected, but currently available tests are inadequate. Metagenomic sequencing can identify almost every globally known infection (bacteria, virus, fungi, parasites) in a sample. Therefore, it has the potential to identify an infection that has caused or triggered ocular inflammation, and as a consequence may help to identify specific treatments. It has the potential to improve our understanding of how to diagnose and treat people with this problem. This study will allow us to test the technique that has been previously optimised for brain infections, on ocular fluids. Participants will be 18 years of age or over and have active ocular inflammation which is suspected to be due to an infection, or an autoimmune process which has been triggered by an infection, but identification of this infection has not been possible using the investigations available as part of standard NHS care. Participants will be identified by the treating clinical team as requiring a sample of fluid from inside of the eye, and some of this fluid will be sent for metagenomic sequencing alongside standard testing. This study will be conducted at Moorfields Eye Hospital, London and will last for approximately a year. Participants will undergo additional non-invasive ocular imaging on the day of their clinic visit, but will not have to attend any additional research visits.",[25,188,189],"Aqueous Humor","Infection",[191,25,188,192],"Metagenomics","Ophthalmology","2025-11-17",{"date":195,"type":33},"2025-11-20",{"date":197,"type":33},"2025-06-12",{"date":199,"type":20},"2026-07-12",{"name":201,"class":40},"Moorfields Eye Hospital NHS Foundation Trust",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":52,"phases":212,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":68},"100476632","phase-3-the-use-of-two-yutiq-versus-sham-for-treatment-of-chronic-non-infectious-intraocular-inflammation-affecting-the-posterior-segment-100476632","NCT05486468","The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment","The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)","TYNI","Inclusion Criteria:\n\nGeneral Inclusion Criteria:\n\n1. Male or non-pregnant female in good general health at least 18 years of age, understands the language of the informed consent, and is willing and able to provide written informed consent and sign\u002Fdate a health information release (HIPAA form) before any study procedures are performed.\n2. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.\n\nOcular Inclusion Criteria (Study Eye):\n\n1. Diagnosed with chronic unilateral or bilateral noninfectious posterior segment inflammation (with or without anterior uveitis) that demonstrated a clinical response to ≥1 previous corticosteroid treatment of any localized type (eg, topical steroid 2 to 4 times per day or intra- or peri-ocular injection) or systemic corticosteroid\u002Fimmunosuppressant treatment with recurrence following treatment indicating chronicity according to the Investigator's judgment.\n2. Presence of active posterior segment inflammation as determined by the Investigator.\n3. Vitreous haze grade ≥ 2 based on the standardization of uveitis nomenclature (SUN) criteria.\n4. Less than 10 anterior chamber cells\u002Fhigh power field determined by slit lamp examination.\n5. Not planning to undergo elective ocular surgery during the study.\n\nExclusion Criteria:\n\nGeneral Exclusion Criteria:\n\n1. Subjects with known hypersensitivity to any components of YUTIQ.\n2. Female subjects who are pregnant or breastfeeding.\n3. Has any acute or chronic medical disease or psychiatric condition that, in the opinion of the Investigator, would preclude participation in the study or put the subject at risk due to study treatment or procedures.\n\nOcular Exclusion Criteria (Study Eye):\n\n1. History of anterior uveitis only (without associated uveitis that affected the posterior segment).\n2. Presence of a vitreous hemorrhage.\n3. Uveitis with infectious etiology.\n4. Intraocular inflammation associated with a condition other than non-infectious uveitis (e.g., intraocular lymphoma).\n5. Current infectious diseases of the cornea and conjunctiva, mycobacterial infections of the eye, or fungal diseases of ocular structures.\n6. Subjects with ACIOL (Anterior Chamber Intraocular Lens) or rupture of the posterior lens capsule.\n7. Diagnosis of any form of glaucoma or ocular hypertension at screening, unless the study eye is being treated with ≤2 intraocular pressure (IOP)-lowering medications and\u002For has been previously treated with an incisional surgical procedure resulting in stable IOP in the normal range (10 to 21 mmHg).\n8. Intraocular pressure \\>21 mmHg or concurrent therapy at screening with \\>2 IOP-lowering pharmacologic agents in the study eye.\n9. Any eye surgery within 12 weeks prior to Day 1 of the study.\n10. Subjects who are unable to attend scheduled follow-up visits throughout the 12-month study.\n11. Has a significant media opacity precluding evaluation of retina and vitreous in the study eye.",{"count":211,"type":20},30,[213],"PHASE3","The Use of Two YUTIQ versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)",[25,216,217,218],"Uveitis, Posterior","Uveitis, Anterior","Uveitis, Intermediate","2025-08-06",{"date":221,"type":33},"2025-08-11",{"date":223,"type":33},"2022-10-05",{"date":225,"type":20},"2026-12",{"name":227,"class":40},"Texas Retina Associates",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":236,"targetDuration":102,"studyType":22,"phases":4,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":259},"100454682","autoinflammatory-disease-alliance-registry-aida-100454682","NCT05200715","AutoInflammatory Disease Alliance Registry (AIDA)","Development of an International Multicenter Registry of Patients With Monogenic and Polygenic Autoinflammatory Diseases Aimed at Clinical and Therapeutical Data Collection and Analysis","AIDA","Inclusion Criteria:\n\n* to be diagnosed with a monogenic AID according to the clinical phenotype and the detection of a confirmative genotype;\n* to be diagnosed with clinical familial Mediterranean fever or Behçet's disease or Still disease or PFAPA syndrome or Schnitzler's disease or CRMO according to the corresponding clinical diagnostic and\u002For classification criteria;\n* to be diagnosed with undifferentiated systemic AID;\n* to be diagnosed with non-infectious uveitis according to the standardization for uveitis nomenclature (SUN) criteria;\n* to be diagnosed with anterior or posterior non-infectious scleritis;\n* to be diagnosed with spondyloarthritis according to ASAS and\u002For New York criteria;\n* to be diagnosed with Castleman disease;\n\nExclusion Criteria:\n\n\\- informed consent\u002Fassent not provided by the patient and\u002For his\u002Fher legal representative.",{"count":237,"type":20},3500,"Autoinflammatory diseases (AID) are clinical entities characterized by recurrent inflammatory attacks in absence of infection, neoplasm or deregulation of the adaptive immune system. Among them, hereditary periodic syndromes, also known as monogenic AID, represent the prototype of this disease group, caused by mutations in genes involved in the regulation of innate immunity, inflammation and cell death. Based on recent experimental acquisitions in the field of monogenic AID, several immunologic disorders have been reclassified as polygenic\u002Fmultifactorial AID, sharing pathogenetic and clinical features with hereditary periodic fevers. This has paved the way to new treatment targets for patients suffering from rare diseases of unknown origin, including Behçet's disease, Still disease, Schnitzler's disease, PFAPA (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis) syndrome, chronic recurrent multifocal osteomyelitis (CRMO), non-infectious uveitis and scleritis. Gathering information on such rare conditions is made difficult by the small number of patients, along with the difficulty of obtaining an accurate diagnosis in non-specialized clinical settings.\n\nIn this context, the AIDA project promotes international collaboration among clinical centres to develop a permanent registry aimed at collecting demographic, genetic, clinical and therapeutic data of patients affected by monogenic and polygenic AID, in order to expand the current knowledge of these rare conditions.",[240,241,242,243,244,245,25,246,247,248,249],"Hereditary Autoinflammatory Diseases","Schnitzler Syndrome","Behcet Syndrome","PFAPA Syndrome","Still Disease","Autoinflammatory Syndrome, Unspecified","Scleritis","Vexas Syndrome","Spondyloarthritis (SpA)","Castleman Disease","2025-07-07",{"date":252,"type":33},"2025-07-10",{"date":254,"type":33},"2020-08-06",{"date":256,"type":20},"2030-08-06",{"name":258,"class":40},"University of Siena",112,{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":52,"phases":270,"briefSummary":272,"conditions":273,"keywords":275,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":287},"100546092","phase-4-therapeutic-drug-monitoring-based-adalimumab-de-escalation-in-non-infectious-chronic-uveitis-100546092","NCT06390436","Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis","Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis: an Open-label, Non-inferiority, Randomised Clinical Trial","SMOOTH","Inclusion Criteria:\n\n* Informed and having signed the study consent form\n* Age ≥ 18 years\n* NICU according to the Standardization of Uveitis Nomenclature (SUN) criteria\n* Complete ophthalmological response for ≥ 48 weeks (96 weeks for uveitis related to Behçet's disease), all treatments combined\n* On ADA 40mg \u002F 14 days for ≥ 24 weeks (i.e. achievement of the steady state for ADA concentrations)\n* Not having received systemic corticosteroid therapy for ≥ 12 weeks\n\nExclusion Criteria:\n\n* Inability or refusal to understand and\u002For sign the informed consent form to participate in the study.\n* Inability and\u002For refusal to carry out the follow-up examinations required for the study.\n* Modification of any background immunomodulatory treatment (e.g. methotrexate, hydroxychloroquine, mycophenolate, etc.) associated with ADA, during the 12 weeks prior to inclusion.\n* Uveitis suspected or proven to be of infectious origin\n* Planned surgery (or other foreseeable medical event) requiring discontinuation of ADA for the duration of the study.",{"count":269,"type":20},320,[271],"PHASE4","Uveitis and its complications are thought to account for 10 to 15% of preventable blindness in Western countries. The diagnosis of chronic non-infectious uveitis (CNUI) can be made after exclusion of pseudo uveitis or infectious uveitis, in the case of any persistent uveitis or uveitis with frequent relapses occurring less than 3 months after cessation of treatment. Adalimumab (ADA), an anti-TNFα monoclonal antibody, has marketing authorization and is widely used in the treatment of UCNI as a relay to corticosteroids. The use of ADA has been optimized, in particular through Therapeutic Drug Monitoring (TDM), based on the determination of serum ADA levels and anti-ADA antibodies. Recently, an article showed that a strategy of spacing ADA administrations in RA patients with concentrations \\>8 μg\u002FmL was not inferior to standard.",[25,274],"Chronic Disease",[276,25,277],"Adalimumab","Therapeutic drug monitoring","2025-06-27",{"date":280,"type":33},"2025-07-01",{"date":282,"type":20},"2025-06",{"date":284,"type":20},"2029-05",{"name":286,"class":40},"Centre Hospitalier Universitaire de Saint Etienne",11,{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":52,"phases":298,"briefSummary":300,"conditions":301,"keywords":303,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":68},"100528487","phase-1-safety-tolerability-and-distribution-of-laquinimod-eye-drops--the-lion-study-100528487","NCT06161415","Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study","Safety, Tolerability, and Distribution of Topical Laquinimod Eye Drops , an Innovative ImmunomodulatOr Targeting Aryl hydrocarboN Receptor (AhR): The LION Study","LION","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Participants who are capable and willing to provide informed consent and follow study instructions.\n3. Participants who are scheduled to undergo pars plana vitrectomy (PPV).\n4. Participants with intraocular pressure (IOP) ≥ 5 mmHg and ≤22 mmHg in study eye\n5. Women who are not pregnant or lactating, are post-menopausal or have undergone a sterilization procedure.\n\nExclusion Criteria:\n\n1. Participants with active periocular or ocular infectious disease (e.g., blepharitis, scleritis, or conjunctivitis, keratitis or endophthalmitis).\n2. Participants with active infectious uveitis\n3. Participants with a history of prior intraocular or extraocular surgery within 90 days of study enrollment\n4. Participant with a history of intravitreal steroids administered to the study eye within 90 days of enrollment.\n5. Participants with a history of intravitreal injection of VEGF inhibitors within 30 days of enrollment\n6. Use of any topical cyclosporine or corticosteroid or other specified (i.e. calcineurin inhibitors) ophthalmic medication in the study eye for any reason within 14 days of enrollment and before the surgery\n7. Use of medication consisting of a strong or moderate inhibitor of CYP3A4 within 2 weeks of Baseline visit (and during the study).\n8. Use of medication consisting of a strong inducer of CYP3A4 within 2 weeks of Baseline visit (and during the study)\n9. Mild, moderate, or severe hepatic impairment (any of Child-Pugh Score A, B, and C)\n10. Moderate or severe renal impairment (GFR ≤60 mL\u002Fmin)\n11. History of HIV disease or other immunodeficiency disorder\n12. History of acute hepatitis A (IgM positive), hepatitis B, or hepatitis C\n13. History of organ or bone marrow transplant\n14. Presence of malignancy under active treatment\n15. Any other acute or chronic medical condition that would, in the judgment of the study investigators, reasonably preclude participation in the clinical study\n16. Already enrolled in a clinical trial.\n17. Any condition that would prevent the investigator from acquiring images of the eye as required per protocol",{"count":297,"type":20},12,[299],"PHASE1","The LION Study is a prospective, single-center phase 1 clinical trial to evaluate the safety, tolerability, and distribution of Laquinimod administered as topical eye drops for two weeks in human participants.",[302,25],"Inflammation",[25,302,304,305,306],"Laquinimod eye drops","Topical","Immunomodulation","2025-05-12",{"date":309,"type":33},"2025-05-14",{"date":311,"type":33},"2024-05-03",{"date":313,"type":20},"2025-07",{"name":315,"class":40},"Quan Dong Nguyen",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":52,"phases":326,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":341},"100469133","screening-for-oculocerebral-lymphoma-with-the-phenotype-of-nk-cells-in-patients-with-uveitis-100469133","NCT05388838","Screening for Oculocerebral Lymphoma with the Phenotype of NK Cells in Patients with Uveitis","Screening for Oculocerebral Lymphoma by Identifying the Phenotype Carried by Circulating NK Cells in Patients with Uveitis","DeLPHy","Inclusion Criteria:\n\nGENERAL CRITERIA\n\n* Male or female over 18 years of age,\n* Free, informed, written consent signed by the patient and the investigator (at the latest on the day of inclusion) and before any examination required by the research,\n* Patient affiliated to the social security system or beneficiary of such a system,\n* Maximum volume of sampling (care + research) per 30-day period to be adapted according to the patient's weight (Order of April 12, 2018 establishing the list of research mentioned in 2° of Article L. 1121-1).\n\nSPECIFIC CRITERIA\n\n\\- Patient affected in one or both eyes: of uveitis with another diagnosis than ocular lymphoma and without cerebral lymphoma (Group 1), or primary ocular lymphoma without brain involvement and never treated (Group 2), or primary ocular lymphoma without brain involvement, treated and considered in remission (IL10 HA level \\\u003C 10) (Group 3), or primary ocular lymphoma without brain involvement, and considered in relapse (IL10 HA level \\> 30) (Group 4), or cerebral lymphoma with or without ocular involvement and without uveitis (Group 5), or cataract (pre- and post-op), glaucoma, retinal detachment or epiretinal retinal detachment or epiretinal membrane, but no brain damage or uveitis (group 6).\n\nExclusion Criteria:\n\n* -GENERAL CRITERIA\n* Patient participating in an ongoing clinical trial at the time of the inclusion visit,\n* Pregnant women, women in labor or nursing mothers,\n* Persons deprived of liberty by a judicial or administrative decision,\n* Persons under psychiatric care,\n* Persons admitted to a health or social institution for purposes other than research,\n* Persons of full age who are subject to a legal protection measure (guardianship, curatorship).\n\nSPECIFIC CRITERIA\n\n* Patient for whom the diagnosis of ocular or cerebral lymphoma is uncertain,\n* Patient with another systemic cancer that is evolving or in remission \\\u003C 2 years.",{"count":325,"type":20},60,[327],"NA","Uveitis is an inflammation of the uvea, an ocular tunic comprising the iris, ciliary body and choroid. This inflammation can also involve other tissues such as the retina, the optic nerve and the aqueous humor. These diseases can result in significant vision loss and account for 10% of all blindness in developed countries, and up to 25% in developing countries. The main difficulty in this pathology is to make the etiological diagnosis, which then allows a specific treatment of the disease. The main etiologie are inflammatory or infectious (sarcoidosis, tuberculosis) but other cancerous etiologies are possible and are of more complicated diagnosis.\n\nVitreoretinal lymphoma is a subtype of central nervous system lymphoma, which is generally associated with a poor prognosis. It is a diffuse non-Hodgkin's lymphoma, with large B cells. It can be primary ocular (Primary Intra-Ocular Lymphoma - LIOP), without brain involvement, but can also be secondary to central nervous system involvement, which explains the poor prognosis of the disease. Approximately 50-90% of LIOP develop brain involvement within 1-2 years of diagnosis, which encourages early diagnosis to avoid brain involvement as much as possible.\n\nThe main obstacle to rapid diagnosis is the difficulty of identifying LIOP. Indeed, the clinical symptoms of this rare disease are often identical to classical uveitis, and the diagnostic means to detect it are invasive and require a trained ophthalmologist and hematologist team. LIOP diagnostic tests are often delay in the management of uveitis and lead to diagnostic erraticity that can last between 4 to 40 months.\n\nThe INSERM U1183 unit is developing a diagnostic technology for lymphomas based on the analysis of blood NK cells and their phenotypes including those acquired by trogocytosis (WO\u002F2016\u002F005548).\n\nA rapid, simple, minimally invasive LIOP test using this technology could therefore be propose to all patients presenting with uveitis and whose clinical criteria could match those of LIOP.\n\nThe research hypothesis is : Could the diagnostic wandering of patients with primary intraocular lymphoma be reduced by a rapid blood test for NK cell phenotype of patients with uveitis? Following a simple blood test, a rapid LIOP test, using this diagnostic technology, could therefore be proposed to all patients with uveitis and clinical criteria (age, intermediate and posterior location of the uveitis) corresponding to those of LIOP.\n\nThe primary objective of this study is to compare the phenotype of circulating NK cells of patient with untreated intraocular lymphoma versus the phenotype of patient with non-cancerous uveitis.",[25,330,331],"Lymphoma","NK-Cell Lymphoma","2025-02-28",{"date":334,"type":33},"2025-03-03",{"date":336,"type":33},"2022-06-01",{"date":338,"type":20},"2025-12-01",{"name":340,"class":40},"Hospices Civils de Lyon",2,{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":52,"phases":352,"briefSummary":353,"conditions":354,"keywords":356,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":68},"100263285","phase-2-intravitreal-adalimumab-versus-subcutaneous-adalimumab-in-non-infectious-uveitis-100263285","NCT02706704","Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis","Efficacy of Intravitreal Adalimumab Compared to Subcutaneous Adalimumab in Patients With Non-infectious Uveitis","IVAS","Inclusion Criteria:\n\n* Subject is ≥ 18 years of age.\n* Subject is diagnosed with non-infectious intermediate-, posterior-, or pan-uveitis.\n* Subject must have active disease at baseline as defined by the presence of at least 1 of the following parameters in at least one eye despite at least 2 weeks of prednisone ≥ 10 mg\u002Fday (or oral corticosteroid equivalent):\n\n  * Active, inflammatory, chorioretinal and\u002For inflammatory retinal vascular lesion\n  * ≥ 1+ anterior chamber cells (Standardization of Uveitis Nomenclature \\[SUN\\] criteria)\n  * ≥ 1+ vitreous haze (National Eye Institute \\[NEI\\]\u002FSUN criteria)\n* Subject with documented prior adequate response to oral corticosteroids (equivalent of oral prednisone up to 1 mg\u002Fkg\u002Fday).\n* If subject is on prednisone \\>=10 mg (or corticosteroid equivalent) at baseline, the dose has not been increased or decreased in the past 14 days.\n* No increase in the immune modulatory therapy in the past three months\n* Negative PPD test.\n* Positive PPD test on anti Tb medications.\n\nExclusion Criteria:\n\n* Subject with isolated anterior uveitis.\n* Subject with confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to TB, cytomegalovirus, lyme disease, toxoplasmosis and herpes simplex virus (HSV).\n* Subject with serpiginous choroidopathy.\n* Subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial.\n* Subject with corneal or lens opacities that preclude the evaluation of the vitreous haze.\n* Subject with uncontrolled high intraocular pressure of ≥ 25 mmHg on maximal therapy.\n* Subject with intermediate uveitis and symptoms and\u002For MRI findings suggestive of a demyelinating disease such as multiple sclerosis. All subjects with intermediate uveitis must have had a prior brain MRI at time of or after diagnosis of intermediate uveitis.\n* Subject has received glucocorticosteroids implant (Retisert®), or Ozurdex within 6 months prior to baseline visit.\n* Subject has received intraocular or periocular corticosteroids or intravitreal methotrexate within 90 days prior to Baseline visit.\n* Subject with proliferative or severe non-proliferative diabetic retinopathy.\n* Subject with neovascular\u002Fwet age-related macular degeneration\n* Subject with abnormality of vitreo-retinal interface (i.e., vitreomacular traction, epiretinal membranes, etc.) with the potential for macular structural damage independent of the inflammatory process.\n* Subject with a systemic inflammatory disease and requires additional therapy with a systemic immunosuppressive agent at the time of study entry.\n* Subjects with history of active or latent Mycobacterium tuberculosis documented by Purified Protein Derivative (PPD) and chest X-ray and not anti tuberculosis (TB) treatment.",{"count":351,"type":20},32,[54],"The objective of this study is to compare and evaluate the efficacy of subcutaneous (40mg) adalimumab biweekly injections to intravitreal adalimumab (1.5 mg\u002F 0.03 mL) administration, given at zero, 2 weeks then every four weeks, in subjects with active non-infectious intermediate-, posterior-, or pan-uveitis.",[25,355],"Non-Infectious Uveitis",[357,358],"Intravitreal Adalimumab","Subcutaneous Adalimumab","2025-02-24",{"date":361,"type":33},"2025-02-26",{"date":363,"type":33},"2016-02",{"date":365,"type":20},"2026-02",{"name":367,"class":40},"American University of Beirut Medical Center",{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":375,"enrollmentInfo":376,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":68},"100495158","the-cohort-study-of-uveitis-patients-100495158","NCT05727540","The Cohort Study of Uveitis Patients","The Cohort Study of Uveitis Patients Based on Real-world Data","Inclusion Criteria:\n\n* The diagnosis is uveitis; The agreement of enrolling this study;\n\nExclusion Criteria:\n\n* Uveitis during the first month after any intraocular surgery; \\\u003C18 years; pregnant and lactating women; other conditions are unsuitable for participation in this study by the investigator such as mental abnormalities.","90 Years",{"count":377,"type":20},600,"This study intends to explore the epidemiology, pathogenesis, clinical manifestations, diagnosis and treatment of uveitis. This is a cohort study. The outcome of the study is the activity of inflammation and visual prognosis. The purpose of this study is to determine the optimal diagnosis and treatment scheme for uveitis patients based on real-world data.",[25],"2024-08-22",{"date":382,"type":33},"2024-08-23",{"date":384,"type":33},"2023-02-20",{"date":386,"type":20},"2026-03-31",{"name":388,"class":40},"Zhongshan Ophthalmic Center, Sun Yat-sen University",{"id":390,"slug":391,"hasResults":11,"nctId":392,"briefTitle":393,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":396,"enrollmentInfo":397,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":68},"100484796","a-study-of-yutiq-018-mg-intravitreal-implant-for-the-management-of-chronic-non-infectious-uveitis-100484796","NCT05592717","A Study of YUTIQ® 0.18 mg Intravitreal Implant for the Management of Chronic Non-infectious Uveitis","An Observational Study of YUTIQ (Fluocinolone Acetonide Intravitreal Implant 0.18 mg) for the Management of Chronic Non-infectious Uveitis","Inclusion Criteria:\n\n1. Male or female in good general health at 18 to 70 years of age.\n2. Presence of unilateral or bilateral non-infectious uveitis affecting the posterior segment\n3. Patients have active inflammation before Yutiq treatment. Subject meets at least 1 of the following criteria: 1. ≥1+ anterior chamber cell and\u002For ≥1+ vitreous haze. 2. Fluorescein angiography demonstrates leakages. 3. OCT images showing the macular edema. 4. The times of relapse in one year are equal to or greater than 3.\n4. Steroids and immunosuppressive agents were discontinued within 3 months after Yutiq injection.\n\nExclusion Criteria:\n\n1. Subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial.\n2. Subject with a history of neurologic symptoms suggestive of central nervous system demyelinating disease.\n3. Prior intravitreal treatment with Retisert®, ILUVIEN®, or YUTIQ® (0.18 mg) within 36 months prior to Day 1.\n4. Prior intravitreal treatment with OZURDEX® within 12 weeks prior to Day 1. Prior intravitreal treatment with Triesence® or TRIVARIS™ (triamcinolone) within 12 weeks prior to Day 1.\n5. Peri-ocular or subtenon steroid treatment within 12 weeks prior to Day 1.\n6. Media opacity precluding evaluation of retina and vitreous (eg, vitreous hemorrhage).\n7. Hypersensitivity to any of the ingredients contained in YUTIQ®.\n8. Any other systemic or ocular condition which, in the judgment of the Investigator, could make the subject inappropriate for study enrollment.\n9. Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in the protocol from at least 14 days prior to Day 1 until the final study visit.","70 Years",{"count":398,"type":20},15,"This project is designed to evaluate the efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious uveitis.",[25,401],"YUTIQ","2024-07-01",{"date":404,"type":33},"2024-07-03",{"date":406,"type":33},"2023-01-05",{"date":408,"type":20},"2026-11-01",{"name":410,"class":40},"Tianjin Medical University",{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":396,"enrollmentInfo":418,"targetDuration":4,"studyType":52,"phases":420,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":68},"100475730","phase-1-minocycline-for-chronic-autoimmune-uveitis-100475730","NCT05474729","Minocycline for Chronic Autoimmune Uveitis","The Efficacy and Safety of Minocycline for Chronic Autoimmune Uveitis","Inclusion Criteria:\n\n* Participant diagnosed of autoimmune diseases with visual function damage (decrease of BCVA, loss of retinal structure)\n* Participant aged from 18-60 years old.\n* Participant that signed the informed consent document and is able to complete the following visits.\n\nExclusion Criteria:\n\n* Participant is allergy to minocycline or tetracyclines.\n* Participant has no contraindications of minocycline or tetracyclines.\n* Participant has an abnormal function of liver, heart, kidney and thyroid.\n* Participant is using glucocorticoids, immunosuppressants or biologics.\n* Female that is pregnant, breast-feeding or planning to become pregnant.\n* Participant that is currently using other medications for other diseases.",{"count":419,"type":20},10,[299,54],"Autoimmune uveitis is one kind of non-infectious, sight-threatening, relapsing and severe ocular disease. Approximately 20%-25% autoimmune uveitis patients suffer from the dilemma of blindness for the chronic and persistent inflammatory state in the eyes, which results in continuous destroy in the structure of the eyes and gradually leads to irreversible damage on visual function. However, it shows limiting efficacy of current treatment including glucocorticoids, immunosuppressant and biologics for chronic autoimmune uveitis. Minocycline has been regarded to have anti-apoptosis and immunemodulatory function for decades and it has been illustrated to be beneficial in several neuro-degenerative and neuro-inflammatory diseases. This trial aims to investigate the efficacy and safety of minocycline for chronic autoimmune uveitis with retinal degenerative changes.",[423,25,424],"Minocycline","Retinal Degeneration","2023-04-16",{"date":427,"type":33},"2023-04-18",{"date":429,"type":33},"2021-12-01",{"date":431,"type":20},"2026-12-31",{"name":433,"class":40},"Sun Yat-sen University",{"id":435,"slug":436,"hasResults":11,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":441,"enrollmentInfo":442,"targetDuration":4,"studyType":52,"phases":444,"briefSummary":445,"conditions":446,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":453,"locationsCount":4},"100447354","phase-4-efficacy-and-safety-of-adalimumab-plus-medium-dose-oral-glucocorticosteroid-for-refractory-behets-uveitis-100447354","NCT05105347","Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis","Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis, Compared With Adalimumab Plus High Dose Oral Glucocorticosteroid, a Non-inferior, Multi-center, Randomized Controlled Trial.","Inclusion Criteria:\n\n* Behçet's disease (BD) patients fulfilling the International Criteria for Behçet's disease (ICBD) published in 2013 with recent recurrence of pan- or posterior uveitis\n* The patient should be on ≥10mg\u002Fd oral prednisone or equivalent\n\nExclusion Criteria:\n\n* Previous treatment with TNFα inhibitors within 3 months\n* Pregnancy, breast feeding women\n* Malignancy\n* Heart failure\n* Demyelinating diseases\n* Renal impairment (creatinine \\> 1.5 mg\u002Fdl)\n* Depression or other psychic disorders\n* History of acute or chronic inflammatory joint or autoimmune disease\n* Patients with severe extra-ocular involvement other than oral\u002Fgenital ulcer and skin involvement\n* Organ or bone marrow transplant recipient, cardiac failure \\> NYHA III\n* Acute liver disease with ALT or SGPT 2x above normal\n* White blood cell count \\\u003C 3500\u002Fmm\\^3\n* Platelet count \\\u003C 100000\u002Fmm\\^3\n* Hgb \\\u003C 8.5g\u002Fdl\n* T-SPOT TB: ≥200 SFCs per 10\\^6 PBMC\n* Active peptic ulcer, systemic or local infection, moderate to severe osteoporosis or other contraindications of intermediate dose corticosteroids\n* Other severe ocular diseases or intraocular surgery within 3 months\n* Media opacity precluding a clear view of the fundus\n* Positive screen test for HBV, HCV, HIV infection or syphilis\n* Body weight \\\u003C45 kg\n* Alcohol abuse or drug abuse\n* Mental impairment\n* Uncooperative attitude","65 Years",{"count":443,"type":20},130,[271],"This study is a multi-center randomized non-inferiority study that aims to observe the short-term (3 months) efficacy and safety of adalimumab plus medium-dose glucocorticosteroid (30mg\u002Fd prednisone or equivalent) with slow tapering for recurrent Behçet's uveitis (BU) attack compared with adalimumab plus high-dose glucocorticosteroid (60mg\u002Fd prednisone or equivalent) with slow tapering.",[25],"2021-11-01",{"date":449,"type":33},"2021-11-03",{"date":451,"type":20},"2021-11-10",{"date":431,"type":20},{"name":454,"class":40},"Peking Union Medical College Hospital"]